Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Beyond MariTide, Amgen has a rich pipeline with more than 30 phase 3 programs. Some are for existing medicines seeking label ...

Shares of Amgen Inc. AMGN slumped 0.73% to $332.80 Tuesday, on what proved to be an all-around mixed trading session for the ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

False Claims Act suit alleging that medical practices engaged in a scheme to overbill Medicare for Amgen Inc. drugs is now dismissed, a New York federal district court said.

In a report released today, Michael Yee from Jefferies assigned a Buy rating to Amgen (AMGN – Research Report), with a price target of ...

An academic partnership to improve diversity in clinical trials has drafted its first industry team members. | An academic ...

The FTC said in its complaint that Amgen would be able to leverage its position with insurance companies and pharmacy benefit managers wanting access to its blockbuster drugs. President Biden is ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $380.00. The ...

With a sold-out crowd and a ton of momentum, Rory McIlroy appeared poised to post his first DP World Tour victory on Northern ...

GOLF fans were left in shock this afternoon as Rasmus Hojgaard earned the 2024 Amgen Irish Open title. But it was heartbreak ...

Rory McIlroy is on familiar soil. Eleven days after a tie for ninth in the Tour Championship, McIlroy fired a first-round 68 ...